| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/GYNO.2001.6194 |
| P8608 | Fatcat ID | release_ltpzkkgtyvgaboxx57digkkb5i |
| P698 | PubMed publication ID | 11371126 |
| P2093 | author name string | Cuello M | |
| Lipkowitz S | |||
| Nau MM | |||
| Ettenberg SA | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| chemotherapy | Q974135 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 380-390 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. | |
| P478 | volume | 81 |
| Q39909763 | 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts |
| Q33564264 | Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells |
| Q35756912 | Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. |
| Q58325213 | An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer |
| Q40354471 | Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model |
| Q39611397 | Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. |
| Q40474530 | Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. |
| Q90427730 | Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin |
| Q33645912 | Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 - markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics |
| Q37506796 | Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway |
| Q53989398 | Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. |
| Q35186676 | Cellular FLICE-inhibitory protein: an attractive therapeutic target? |
| Q90113351 | Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer |
| Q48035648 | Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. |
| Q40025662 | Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells |
| Q40639389 | Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. |
| Q61853694 | Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer |
| Q38103591 | Death receptors as targets in cancer |
| Q37660616 | Death receptors: targets for cancer therapy |
| Q37319386 | Directing cancer cells to self-destruct with pro-apoptotic receptor agonists |
| Q91812392 | Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential |
| Q36628057 | Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis |
| Q53570905 | Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. |
| Q39835805 | Endonucleases induced TRAIL-insensitive apoptosis in ovarian carcinoma cells |
| Q40563380 | Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. |
| Q42176172 | Ethanolic extract of Thevetia peruviana flowers enhances TNF-α and TRAIL-induced apoptosis of human cervical cancer cells via intrinsic and extrinsic pathways |
| Q39325378 | Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy |
| Q42183082 | Extracellular Caspase-8 Dependent Apoptosis on HeLa Cancer Cells and MRC-5 Normal Cells by ICD-85 (Venom Derived Peptides). |
| Q40947112 | Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells |
| Q36424294 | In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus |
| Q40751233 | Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. |
| Q24672792 | Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics |
| Q34425447 | Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling |
| Q24798681 | Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis |
| Q38557486 | Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. |
| Q37280136 | Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells |
| Q28478861 | Mitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drug |
| Q44403032 | Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells |
| Q47628054 | Molecular requirements for the combined effects of TRAIL and ionising radiation |
| Q44757357 | N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines |
| Q42373863 | N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cells |
| Q30479062 | Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis |
| Q36427134 | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| Q84575154 | Overcoming TRAIL resistance in ovarian carcinoma |
| Q40560857 | Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms |
| Q35045233 | P-glycoprotein is not involved in pathway of anti-Fas/Fas-induced apoptosis in KBv200 cells |
| Q38358514 | Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines |
| Q44905141 | Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation |
| Q35756907 | Potential for TRAIL as a therapeutic agent in ovarian cancer |
| Q36222691 | Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells |
| Q40533876 | Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. |
| Q41640538 | Schistosoma japonicum egg antigen up-regulates fibrogenesis and inhibits proliferation in primary hepatic stellate cells in a concentration-dependent manner |
| Q47328097 | Shell effects on acoustic performance of a drug-delivery system activated by ultrasound. |
| Q45108559 | Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter |
| Q39774066 | Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol |
| Q44389071 | Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway |
| Q37480340 | TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. |
| Q35756909 | TRAIL and chemotherapeutic drugs in cancer therapy |
| Q37972139 | TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. |
| Q36572530 | TRAIL receptor-targeted therapy. |
| Q39263297 | TRAIL-NP hybrids for cancer therapy: a review. |
| Q39197722 | TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells |
| Q35609438 | Targeted ovarian cancer treatment: the TRAILs of resistance. |
| Q90647016 | The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer |
| Q24811656 | The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice |
| Q34428852 | The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells |
| Q40105328 | The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium |
| Q55181844 | The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells. |
| Q37181734 | To kill a tumor cell: the potential of proapoptotic receptor agonists |
| Q36865726 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. |
Search more.